Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert W Robey

Showing results (41-50 of 122) with videos related to

Pageof 13
Sort By:
Cancer Chemotherapy and Pharmacology|April 20, 2005
Single nucleotide polymorphisms modify the transporter activity of ABCG2Kuniaki Morisaki, Robert W Robey, Csilla Ozvegy-Laczka, et al.
Cancer Biology & Therapy|February 22, 2007
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patientsJing Li, George Cusatis, Julie Brahmer, et al.
Advanced Nanobiomed Research|January 19, 2026
Self-Assembled Verteporfin Nanoparticles for Photodynamic and Light-Independent Therapy in GlioblastomaJohn A Quinlan, Kaylin Baumiller, Anandita Gaur, et al.
Cancer Biology & Therapy|November 30, 2012
Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migrationCaterina Ierano, Agnes Basseville, Kenneth K W To, et al.
Cancer Drug Resistance (Alhambra, Calif.)|February 11, 2026
Identification of antibody-drug conjugate payloads that are substrates of ATP-binding cassette drug efflux transportersJacob S Roth, Hui Guo, Lu Chen, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Identification of antibody-drug conjugate payloads which are substrates of ATP-binding cassette drug efflux transportersJacob S Roth, Hui Guo, Lu Chen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 23, 2013
Overlapping substrate and inhibitor specificity of human and murine ABCG2Joshua Bakhsheshian, Matthew D Hall, Robert W Robey, et al.
Blood|March 5, 2004
T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistanceRichard L Piekarz, Robert W Robey, Zhirong Zhan, et al.
Biochemistry|January 22, 2010
Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2Orsolya Polgar, Caterina Ierano, Akina Tamaki, et al.
Cell Cycle (Georgetown, Tex.)|August 23, 2013
Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitorsCaterina Ierano, Arup R Chakraborty, Alina Nicolae, et al.
Pageof 13

Showing results (41-50 of 122) with videos related to

Sort By:
Pageof 13
Cancer Chemotherapy and Pharmacology|April 20, 2005
Single nucleotide polymorphisms modify the transporter activity of ABCG2Kuniaki Morisaki, Robert W Robey, Csilla Ozvegy-Laczka, et al.
Cancer Biology & Therapy|February 22, 2007
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patientsJing Li, George Cusatis, Julie Brahmer, et al.
Advanced Nanobiomed Research|January 19, 2026
Self-Assembled Verteporfin Nanoparticles for Photodynamic and Light-Independent Therapy in GlioblastomaJohn A Quinlan, Kaylin Baumiller, Anandita Gaur, et al.
Cancer Biology & Therapy|November 30, 2012
Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migrationCaterina Ierano, Agnes Basseville, Kenneth K W To, et al.
Cancer Drug Resistance (Alhambra, Calif.)|February 11, 2026
Identification of antibody-drug conjugate payloads that are substrates of ATP-binding cassette drug efflux transportersJacob S Roth, Hui Guo, Lu Chen, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Identification of antibody-drug conjugate payloads which are substrates of ATP-binding cassette drug efflux transportersJacob S Roth, Hui Guo, Lu Chen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 23, 2013
Overlapping substrate and inhibitor specificity of human and murine ABCG2Joshua Bakhsheshian, Matthew D Hall, Robert W Robey, et al.
Blood|March 5, 2004
T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistanceRichard L Piekarz, Robert W Robey, Zhirong Zhan, et al.
Biochemistry|January 22, 2010
Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2Orsolya Polgar, Caterina Ierano, Akina Tamaki, et al.
Cell Cycle (Georgetown, Tex.)|August 23, 2013
Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitorsCaterina Ierano, Arup R Chakraborty, Alina Nicolae, et al.
Pageof 13